3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
2
Myeloid
1
Lymphoid
1
Classical hematology
1
Conditions
Neutropenia
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Leukemia, Myeloid, Acute
1
Interventions
Specimen Handling
3
Biopsy
3
venetoclax
2
selinexor
2
luspatercept
2
Tacrolimus
2
Lymphatic Irradiation
2
Imatinib Mesylate
2
Busulfan
2
Azacitidine
2
trametinib
1
tagraxofusp
1
peginterferon alfa-2b
1
olutasidenib
1
nilotinib
1
flumatinib
1
fludarabine phosphate
1
fludarabine
1
decitabine and cedazuridine drug combination
1
dabrafenib
1
Tyrosine Kinase Inhibitors
1
Thiotepa
1
Spectroscopy, Near-Infrared
1
Sirolimus
1
Single-Cell Gene Expression Analysis
1
Resistance Training
1
Receptors, Antigen, T-Cell
1
Quality of Life
1
Pleurodesis
1
Phlebotomy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Not yet recruiting
×
Levofloxacin
×
Myeloid
×
Clear all
NCT07528417
2026-04-22
MYELO-CAN:ABX
University of Manitoba
Phase 2
Not yet recruiting
75 enrolled